MX2016006674A - Metodos para la conjugacion de oxima con polipeptidos modificados con cetona. - Google Patents
Metodos para la conjugacion de oxima con polipeptidos modificados con cetona.Info
- Publication number
- MX2016006674A MX2016006674A MX2016006674A MX2016006674A MX2016006674A MX 2016006674 A MX2016006674 A MX 2016006674A MX 2016006674 A MX2016006674 A MX 2016006674A MX 2016006674 A MX2016006674 A MX 2016006674A MX 2016006674 A MX2016006674 A MX 2016006674A
- Authority
- MX
- Mexico
- Prior art keywords
- ketone
- protein
- oxime
- payload
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
Abstract
La invención proporciona métodos mejorados para preparar conjugados de proteína a partir de una proteína modificada con cetona. En una modalidad, la proteína se prepara mediante el enlace de dos cisteínas libres mediante la reacción con una 1,3-di-halo-acetona o con un reactivo que contenga cetona similar, enlazando los átomos de azufre de las dos cisteínas entre sí. La cetona insertada entre los átomos de azufre se utiliza entonces para formar una oxima, conjugando de esta manera la proteína con una carga útil. En otra modalidad, se enlazan dos residuos de cisteína entre sí mediante la reacción con una 1,3-di-halo-acetona o con un reactivo similar, y la nueva cetona se utiliza para formar una oxima con una molécula de carga útil adecuada, conjugando de esta manera la proteína con una carga útil. El método proporciona condiciones de reacción mejoradas para la formación de oxima, en donde se logran rendimientos más altos y una mayor homogeneidad del producto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361909236P | 2013-11-26 | 2013-11-26 | |
US201462002614P | 2014-05-23 | 2014-05-23 | |
PCT/IB2014/066300 WO2015079376A1 (en) | 2013-11-26 | 2014-11-24 | Methods for oxime conjugation to ketone-modified polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016006674A true MX2016006674A (es) | 2016-12-09 |
Family
ID=52117931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016006674A MX2016006674A (es) | 2013-11-26 | 2014-11-24 | Metodos para la conjugacion de oxima con polipeptidos modificados con cetona. |
Country Status (15)
Country | Link |
---|---|
US (1) | US10172948B2 (es) |
EP (1) | EP3074048B1 (es) |
JP (1) | JP6609563B2 (es) |
KR (1) | KR20160088429A (es) |
CN (1) | CN105764530B (es) |
AU (1) | AU2014356126B2 (es) |
CA (1) | CA2928087A1 (es) |
EA (1) | EA201691075A1 (es) |
ES (1) | ES2729643T3 (es) |
IL (1) | IL245244A0 (es) |
MX (1) | MX2016006674A (es) |
TW (1) | TWI572361B (es) |
UY (1) | UY35854A (es) |
WO (1) | WO2015079376A1 (es) |
ZA (1) | ZA201602603B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2925368B1 (en) | 2012-11-30 | 2019-03-27 | Novartis AG | Methods for making conjugates from disulfide-containing proteins |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
WO2017051254A1 (en) * | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
US11413353B2 (en) | 2015-11-25 | 2022-08-16 | Legochem Biosciences, Inc. | Conjugates comprising self-immolative groups and methods related thereto |
EP3380126A4 (en) | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS |
JP7002733B2 (ja) * | 2016-11-18 | 2022-02-04 | 国立大学法人 鹿児島大学 | IgG結合ペプチドを含む固相担体及びIgGの分離方法 |
CA3058360A1 (en) | 2017-03-29 | 2018-10-04 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
MX2020011554A (es) | 2018-05-09 | 2020-11-24 | Legochem Biosciences Inc | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19). |
KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239110B1 (en) | 1990-02-22 | 2001-05-29 | W.R. Grace & Co. -Conn. | Synthetic analogs of thrombospondin and therapeutic use thereof |
WO1999013062A1 (en) | 1997-09-09 | 1999-03-18 | Nycomed Imaging As | Factors vii fragments and analogs thereof and their use in the treatment of blood clotting disorders |
WO1999013063A1 (en) | 1997-09-09 | 1999-03-18 | Nycomed Imaging As | Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders |
GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
US20090131306A1 (en) | 2007-06-15 | 2009-05-21 | Adherex Technologies, Inc. | Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor |
WO2010025510A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
EP2889624B1 (en) | 2009-08-10 | 2018-10-03 | UCL Business PLC | Reversible covalent linkage of functional molecules |
WO2014059028A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
US9428589B2 (en) | 2012-11-15 | 2016-08-30 | Brandeis University | Tethering cysteine residues using cyclic disulfides |
EP2925368B1 (en) | 2012-11-30 | 2019-03-27 | Novartis AG | Methods for making conjugates from disulfide-containing proteins |
-
2014
- 2014-11-24 EA EA201691075A patent/EA201691075A1/ru unknown
- 2014-11-24 KR KR1020167016645A patent/KR20160088429A/ko not_active Application Discontinuation
- 2014-11-24 WO PCT/IB2014/066300 patent/WO2015079376A1/en active Application Filing
- 2014-11-24 CA CA2928087A patent/CA2928087A1/en not_active Abandoned
- 2014-11-24 AU AU2014356126A patent/AU2014356126B2/en not_active Ceased
- 2014-11-24 US US14/551,187 patent/US10172948B2/en active Active
- 2014-11-24 CN CN201480064270.7A patent/CN105764530B/zh not_active Expired - Fee Related
- 2014-11-24 JP JP2016554939A patent/JP6609563B2/ja not_active Expired - Fee Related
- 2014-11-24 ES ES14815051T patent/ES2729643T3/es active Active
- 2014-11-24 MX MX2016006674A patent/MX2016006674A/es unknown
- 2014-11-24 EP EP14815051.9A patent/EP3074048B1/en not_active Not-in-force
- 2014-11-25 UY UY0001035854A patent/UY35854A/es not_active Application Discontinuation
- 2014-11-25 TW TW103140861A patent/TWI572361B/zh not_active IP Right Cessation
-
2016
- 2016-04-15 ZA ZA2016/02603A patent/ZA201602603B/en unknown
- 2016-04-20 IL IL245244A patent/IL245244A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2016539190A (ja) | 2016-12-15 |
JP6609563B2 (ja) | 2019-11-20 |
EP3074048B1 (en) | 2019-03-06 |
ZA201602603B (en) | 2017-06-28 |
US20150150998A1 (en) | 2015-06-04 |
TWI572361B (zh) | 2017-03-01 |
WO2015079376A1 (en) | 2015-06-04 |
US10172948B2 (en) | 2019-01-08 |
UY35854A (es) | 2015-06-30 |
EA201691075A1 (ru) | 2016-09-30 |
ES2729643T3 (es) | 2019-11-05 |
AU2014356126B2 (en) | 2017-01-05 |
EP3074048A1 (en) | 2016-10-05 |
TW201524520A (zh) | 2015-07-01 |
KR20160088429A (ko) | 2016-07-25 |
AU2014356126A1 (en) | 2016-05-19 |
CN105764530A (zh) | 2016-07-13 |
IL245244A0 (en) | 2016-06-30 |
CN105764530B (zh) | 2019-09-13 |
CA2928087A1 (en) | 2015-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016006674A (es) | Metodos para la conjugacion de oxima con polipeptidos modificados con cetona. | |
ZA201805853B (en) | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | |
IN2015DN02913A (es) | ||
PH12018500285A1 (en) | Bridge linkers for conjugation of a cell-binding molecule | |
PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
MY186708A (en) | Constructs targeting afp peptide/mhc complexes and uses thereof | |
MX2018015271A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
PH12019501438A1 (en) | Anti-pd-1 antibody and use thereof | |
PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
PH12018501042A1 (en) | Antibodies and antibody fragments for site-specific conjugation | |
MX2017011281A (es) | Conjugados de amatoxina y anticuerpos. | |
MX2018014227A (es) | Proteinas de union de cadena unica de fragmento variable cd3. | |
MX2019006043A (es) | Proteína de unión de antígeno prostático específico de membrana. | |
MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MX2015010146A (es) | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2017005199A (es) | Conjugados y reactivos de conjugacion. | |
MX2021015825A (es) | Formulaciones de anticuerpos estables acuosas. | |
MY193985A (en) | Antibody drug conjugates for ablating hematopoietic stem cells | |
MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. | |
PH12020550596A1 (en) | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
MX2018010491A (es) | Proceso para la preparacion de un conjugado anticuerpo-rifamicina. |